Careers  |  Sign In  |  Register  |   Twitter

FDA Approves Dalavance for Treatment of MRSA

CNN News reports that the FDA has now approved Durata Therapeutics‘ new drug, Dalavance, for the treatment of bacterial skin infections like Methicillin-resistant Staphylococcus aureus, also known as MRSA. The article explains that what makes Dalavance different from other MRSA drugs is that it has been labeled a Qualified Infectious Disease Product (QIDP). “Any drug designated QIDP by the FDA gets a priority review and expedited review process. If approved the drug also then qualifies for an additional five years of marketing exclusivity.” The agency hopes that such a designation will encourage companies to develop drugs that target such epidemic infections.

Read the article published by CNN News.